CN Patent

CN119685469A — 脓毒症急性肾损伤的新诊治标志物cd36及应用

Assigned to Chongqing Medical University · Expires 2025-03-25 · 1y expired

What this patent protects

本发明提供了脓毒症急性肾损伤(Sepsis‑induced acute kidney injury,SAKI)的新型生物标志物CD36在检测、诊断、治疗SAKI中的应用。本发明利用生物信息学分析探究证实在人群中肾脏CD36与SAKI有很好的相关性，同时在动物模型上也得以验证，从而为SAKI的临床诊治提供了新的诊治标志物，具有重要的临床意义。

USPTO Abstract

本发明提供了脓毒症急性肾损伤(Sepsis‑induced acute kidney injury,SAKI)的新型生物标志物CD36在检测、诊断、治疗SAKI中的应用。本发明利用生物信息学分析探究证实在人群中肾脏CD36与SAKI有很好的相关性，同时在动物模型上也得以验证，从而为SAKI的临床诊治提供了新的诊治标志物，具有重要的临床意义。

Drugs covered by this patent

Patent Metadata

Patent number
CN119685469A
Jurisdiction
CN
Classification
—
Expires
2025-03-25
Drug substance claim
No
Drug product claim
No
Assignee
Chongqing Medical University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.